Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antihypertensive drugs
Biotech
In deal fraud dispute with Novo, KBP looks to revive heart drug
KBP could move to conduct another phase 3 trial, potentially pursuing a smaller indication with the FDA, according to a person close to the situation.
Angus Liu
Apr 1, 2026 2:30am
AstraZeneca's $1.3B bet reduced BP by 14 mmHg over 12 weeks
Nov 10, 2025 6:15am
AstraZeneca's $1.3B bet yields 2nd phase 3 blood pressure win
Oct 7, 2025 4:01am
Novo Nordisk vs. KBP: From $1.3B deal to legal battlefield
Oct 2, 2025 3:00am
With no Tryvio buyer, Idorsia recoups $100M from Viatris deal
Feb 26, 2025 7:00am
J&J hands back $230M blood pressure drug with approval in sight
Sep 6, 2023 6:20am
